N
Norbert Ifrah
Researcher at French Institute of Health and Medical Research
Publications - 308
Citations - 17248
Norbert Ifrah is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Transplantation & Myeloid leukemia. The author has an hindex of 66, co-authored 298 publications receiving 15698 citations. Previous affiliations of Norbert Ifrah include University of Angers.
Papers
More filters
Journal ArticleDOI
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Michel Attal,Jean-Luc Harousseau,Anne-Marie Stoppa,Jean-Jacques Sotto,Jean-Gabriel Fuzibet,Jean-François Rossi,Philippe Casassus,Hervé Maisonneuve,Thierry Facon,Norbert Ifrah,Catherine Payen,Régis Bataille +11 more
TL;DR: The response rate among the patients who received high-dose therapy was 81 percent, whereas it was 57 percent in the group treated with conventional chemotherapy (P<0.001).
Journal ArticleDOI
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials
Robert Kerrin Hills,Sylvie Castaigne,Frederick R. Appelbaum,Jacques Delaunay,Stephen H. Petersdorf,Megan Othus,Elihu H. Estey,Hervé Dombret,Sylvie Chevret,Norbert Ifrah,Jean-Yves Cahn,Christian Recher,Lucy Chilton,Anthony V. Moorman,Alan Kenneth Burnett +14 more
TL;DR: Gemtuzumab ozogamicin can be safely added to conventional induction therapy and provides a significant survival benefit for patients without adverse cytogenetic characteristics, and its licence status might need to be reviewed.
Journal ArticleDOI
Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium Infusions: A Retrospective Study of 161 Patients Receiving Oxaliplatin Combined with 5-Fluorouracil and Leucovorin for Advanced Colorectal Cancer
Laurence Gamelin,Michèle Boisdron-Celle,Remy Delva,Veronique Guerin-Meyer,Norbert Ifrah,Alain Morel,Erick Gamelin +6 more
TL;DR: Ca/Mg infusions seem to reduce incidence and intensity of acute oxaliplatin-induced symptoms and might delay cumulative neuropathy, especially in 85 mg/m2 oxali Platin dosage.
Journal ArticleDOI
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia - Results of the GRAAPH-2003 study
Adrienne de Labarthe,Philippe Rousselot,Francoise Huguet-Rigal,Eric Delabesse,Francis Witz,Sébastien Maury,Delphine Rea,Jean-Michel Cayuela,M C Vekemans,Oumedaly Reman,Agnes Buzyn,Arnaud Pigneux,Martine Escoffre,Yves Chalandon,Elizabeth Macintyre,Véronique Lhéritier,Jean-Paul Vernant,Xavier Thomas,Norbert Ifrah,Hervé Dombret +19 more
TL;DR: This study confirms the value of the combined approach and encourages prospective trials to define the optimal chemotherapy that has to be combined with imatinib and to carefully reevaluate the place of allogeneic SCT in this new context.
Journal ArticleDOI
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
Eric Jourdan,Nicolas Boissel,Sylvie Chevret,Eric Delabesse,Aline Renneville,Pascale Cornillet,Odile Blanchet,Jean-Michel Cayuela,Christian Recher,Emmanuel Raffoux,Jacques Delaunay,Arnaud Pigneux,Claude-Eric Bulabois,Céline Berthon,Cécile Pautas,Norbert Vey,Bruno Lioure,Xavier Thomas,Isabelle Luquet,Christine Terré,Philippe Guardiola,Marie C. Béné,Claude Preudhomme,Norbert Ifrah,Hervé Dombret +24 more
TL;DR: It is suggested that MRD, rather than gene mutations, should be used for future treatment stratifications in CBF-AML patients, as the sole prognostic factor in multivariate analysis.